Analyst Research and Ratings: Castlight Health, Inc. (CSLT), Zscaler, Inc. (ZS)

Castlight Health, Inc. (NYSE:CSLT) tinted gains of +23.82% (+0.76 points) to US$3.95. The volume of 2.41 Million shares climbed down over an trading activity of 473.35 Million shares. EPS ratio determined by looking at last 12 month figures is -0.73. Over the same time span, the stock marked US$5.95 as its best level and the lowest price reached was US$1.86. The corporation has a market cap of US$545.18 Million.

Castlight Health, Inc. (NYSE:CSLT)’s earnings per share has been growing at a -16.8 percent rate over the past 5 year when average revenue increase was noted as 99.5 percent. The return on equity ratio or ROE stands at -22.1 percent while most common profitability ratio return on investment (ROI) was -51.1 percent. The company’s institutional ownership is monitored at 76.1 percent. The company’s net profit margin has achieved the current level of -29.2 percent and possesses 61.1 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 5 think it is Hold. Recently, analysts have updated the overall rating to 2.33. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Zscaler, Inc. (NASDAQ:ZS) is worth US$7.39 Billion and has recently risen 21.92% to US$60.57. The latest exchange of 9.65 Million shares is above its average trading activity of 1.76 Million shares. The day began at US$57.49 but the price moved to US$55.3 at one point during the trading and finally capitulating to a session high of US$61.14. The stock tapped a 52-week high of US$51.36 while the mean 12-month price target for the shares is US$44.75.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 28.98, and a price to sales ratio of 34.59. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 30.9%, it carries an earnings per share ratio of -0.28.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 3 brokerage firms polled by Factset Research. At present, 7 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 1 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.4.